Hangyu Ji, Xuefei Zhao, Xinyan Chen, Hui Fang, Huailin Gao, Geng Wei, Min Zhang, Hongyu Kuang, Baijing Yang, Xiaojun Cai, Yanjin Su, Chunli Piao, Shuyu Zhao, Liyang Li, Wenliang Sun, Tianshu Xu, Qinghua Xu, Yuan Fan, Jianhua Ye, Chen Yao, Meixia Shang, Guangyao Song, Liming Chen, Qingshan Zheng, Xinhua Xiao, Li Yan, Fengmei Lian, Xiaolin Tong, Zhenhua Jia
IMPORTANCE: Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA1c), and improve insulin resistance in people with type 2 diabetes. OBJECTIVE: To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023...
June 3, 2024: JAMA Internal Medicine